期刊
BRITISH JOURNAL OF CANCER
卷 108, 期 5, 页码 1034-1041出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2013.58
关键词
sunitinib; sarcopenia; angiogenesis inhibitors; renal cell carcinoma; VEGF-A; treatment outcomes
类别
Background: Little is known on factors predicting sunitinib toxicity. Recently, the condition of low muscle mass, named sarcopenia, was identified as a significant predictor of toxicity in metastatic renal cell cancer (mRCC) patients treated with sorafenib. We investigated whether sarcopenia could predict early dose-limiting toxicities (DLTs) occurrence in mRCC patients treated with sunitinib. Methods: Consecutive mRCC patients treated with sunitinib were retrospectively reviewed. A DLT was defined as any toxicity leading to dose reduction or treatment discontinuation. Body composition was evaluated using CT scan obtained within 1 month before treatment initiation. Results: Among 61 patients eligible for analysis, 52.5% were sarcopenic and 32.8% had both sarcopenia and a body mass index (BMI) <25 kg m(-2). Eighteen patients (29.5%) experienced a DLT during the first cycle. Sarcopenic patients with a BMI<25 kg m(-2) experienced more DLTs (P = 0.01; odds ratio = 4.1; 95% CI: (1.3-13.3)), more cumulative grade 2 or 3 toxicities (P = 0.008), more grade 3 toxicities (P = 0.04) and more acute vascular toxicities (P = 0.009). Conclusion: Patients with sarcopenia and a BMI<25 kg m(-2) experienced significantly more DLTs during the first cycle of treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据